During a US Food and Drug Administration (FDA) facility inspection, the most visible activity typically occurs in the so-called “front room,” where company representatives respond to investigator questions and provide requested information. But seasoned quality and regulatory leaders know that a well-organized “back room” often serves as the engine of the inspection effort, helping teams locate records, prepare experts, anticipate agency requests, and more.
The back room functions as the operational hub supporting those activities. It’s where records are gathered, reviewed, analyzed, and prepared before being provided to the FDA, while teams coordinate responses, identify potential issues, prepare subject matter experts (SMEs), and manage the flow of information throughout the inspection.
A well-oiled back room can help reduce surprises, improve communication, and keep inspection activities moving efficiently. QualityHub Corporate VP Sean Boyd and QHub Principal Consultants Elisabeth George and Melinda Novatny say a successful back room depends on having the right people in place, clearly defined responsibilities, and strong coordination between personnel supporting the inspection behind the scenes and those interacting directly with agency investigators.
Below are five back-room tips from Boyd, George, and Novatny.
1. Staff the Back Room With Knowledgeable, Experienced Personnel
One of the biggest misconceptions about a back room is that its primary job is simply retrieving documents. In reality, the people working there should be actively reviewing records before they reach investigators.
“You need to have very intelligent people in the back room because they should be reviewing those records before they’re brought into the front room,” consultant George said, adding that back-room staffers should also understand the records they’re reviewing and be familiar with the processes behind them.
“Their role is to identify potential issues before investigators do and communicate concerns to front-room personnel who may not have recently reviewed the documents in question,” she told QHub Insights. “They should know what the issues are and be able to communicate that to the front-room person who has to talk about those issues with the investigator.”
That review can be particularly valuable when examining lengthy quality records, validation reports, test reports, or production documentation, George said. She noted that reviewers should pay close attention to missing information, transcription errors, inconsistent entries, and other details that investigators often identify quickly.
“For FDA investigators, that’s the kind of stuff they love,” George warned. “Those are easy problems for investigators to find – those are the low-hanging fruit.”
She further recommends building a team with multiple functions, including document reviewers, runners who can retrieve records from across the facility, and individuals who understand the organization’s operations well enough to know where information can be found quickly. An experienced coordinator can help prioritize requests and keep activities organized as inspection demands increase.
2. Establish Clear Communication Between Front and Back Rooms
Even the strongest back-room team can struggle if communication breaks down. Maintaining a continuous flow of information between both rooms helps ensure that document requests, investigator concerns, potential follow-up questions, and other emerging issues are communicated quickly.
George recommends assigning specific individuals to facilitate communication throughout the inspection. Many companies use collaboration platforms such as Microsoft Teams or Slack to provide real-time updates on investigator activity.
“You want people in the front room that are prepared to talk with the investigator and do so professionally.” – Sean Boyd
“The front room should have a scribe who’s typing into Teams, and the back room should have a reader who can tell the others in the back room, ‘Hey, we need this document,’ or ‘Hey, the FDA wants to talk to this SME,’ or whatever it may be,” she said.
In George’s experience, effective communication extends beyond document requests. Information should also be shared about investigator reactions, areas of interest, and discussions occurring in the front room. This approach allows the back room to anticipate future requests and prepare experts before they’re needed. If investigators begin focusing on a particular process or department, back-room staffers can start gathering records and briefing personnel before formal requests are made.
The result is a more coordinated response process that reduces delays and helps companies remain proactive throughout the inspection.
3. Keep SMEs Ready and Available – But Make Sure They’re Good Communicators
Subject matter experts play an important role during FDA inspections, but manufacturers should think carefully about how those experts are deployed.
Consultant Novatny recommends identifying and preparing SMEs well before an inspection begins. Those experts should be reviewing relevant records, monitoring inspection trends, and preparing for potential questions related to their areas of expertise.
“Have those subject matter experts at the ready in the back room, because they are the ones that should be really reviewing those records and follow up requests or records that are likely to come through during the inspection,” she said.
However, Novatny cautions that technical expertise and communication skills are not always found in the same person. Some experts excel at analyzing data and explaining complex systems internally but may not be the best choice for engaging with investigators.
“There are subject matter experts who are very, very technically astute but they can’t communicate effectively,” she said.
QualityHub’s Boyd emphasized that companies should evaluate more than technical knowledge when determining which SMEs should interact directly with FDA investigators. The ability to communicate clearly, remain professional under pressure, and represent the organization effectively are critical considerations.
“You want people in the front room that are prepared to talk with the investigator and do so professionally,” he said.
Even more importantly than those staffing the back room, Boyd noted that front-room representatives need to be able to think on their feet while staying aligned with the company’s inspection strategy and the information FDA is seeking.
Manufacturers should evaluate both technical competence and communication effectiveness when deciding which SME should appear in the front room if needed. Internal audits, mock inspections, and interview rehearsals can help identify which experts perform best under questioning and which are more effective supporting activities from behind the scenes.
Boyd explained that FDA readiness activities can help companies determine where each expert can add the most value.
“When a company conducts internal audits, it will get a sense of who performs well, especially under pressure,” Boyd said. “And when you do mock inspections or mock interviews, you’re going to determine who is a good front-room speaker – an appropriate FDA-facing person.”
In some cases, both types of individuals may be needed. One can provide technical support and coaching in the back room while another delivers concise and accurate responses in front of investigators. The back-room expert can help ensure responses are supported by objective evidence while allowing the front-room representative to maintain a clear and effective dialogue with investigators.
4. Avoid Having Too Many ‘Cooks in the Kitchen’
A common challenge during inspections is managing the number of employees populating the back room. While support is important, having too many people performing overlapping tasks can create confusion and slow response times.
Consultant George recommends establishing a formal inspection process that clearly defines roles, responsibilities, competencies, and reporting relationships before an inspection begins.
“Their roles and responsibilities have to be made very clear,” she said.
“I would definitely have a backup or an understudy for any front- or back-room representative, should something happen that they can’t be on site for part or all of the inspection.” – Sean Boyd
Without that structure, multiple people may attempt to retrieve the same records, answer the same questions, or provide conflicting direction. The resulting confusion can affect both the back room and the front room.
“If you have too many cooks in the kitchen, you’re probably going to step on each other’s toes,” George said.
For a typical mid-sized company, George estimates that roughly five people can effectively support a back-room operation. Those roles may include a communications lead, document reviewers, runners, and an overall coordinator responsible for managing activities and setting priorities.
Meanwhile, larger organizations will likely require significantly larger teams. George noted that some of these facilities may have as many as 10 people supporting inspection activities behind the scenes, while leadership personnel monitor communications and remain available if their expertise is needed.
Having a defined hierarchy also helps when experts are called into the front room. Before entering, personnel can be briefed on previous discussions, current investigator concerns, and expectations for answering questions.
5. Develop Backup Plans for Critical Roles
Inspection readiness planning should account for unexpected disruptions. Employees may become unavailable due to illness, travel, family emergencies, or other circumstances, making backup personnel essential.
George advises organizations to avoid assigning any critical inspection responsibility to a single individual, pointing out that “no role should operate in isolation.”
Cross-training employees and establishing role-specific training programs can help maintain inspection readiness if key personnel become unavailable. Some organizations also identify backup resources who are trained to support multiple inspection activities and can step into different roles when needed.
George said manufacturers would be wise to identify “multiple potential backups” well before an inspection occurs rather than scrambling to fill gaps after an investigator arrives.
QualityHub’s Boyd agreed that inspection teams should prepare primary and backup personnel in parallel as part of broader inspection readiness activities.
“I would definitely have a backup or an understudy for any front- or back-room representative, should something happen that they can’t be on site for part or all of the inspection,” Boyd said. “Preparing your lead and backup in parallel as you’re doing your inspection readiness activities” helps ensure continuity when unexpected issues arise.
Beyond assigning a direct backup, Boyd noted that companies should also consider other employees outside the immediate department who may be able to provide support when needed, especially in specialized areas of the quality system. Building a larger pool of trained resources can help ensure the company is prepared if key experts are unavailable.
While FDA investigators may occasionally demonstrate flexibility when unexpected circumstances arise, organizations should not assume schedules can be adjusted. Consultant George recalled situations where investigators worked with companies to accommodate staffing challenges, but she emphasized that outcomes can vary depending on the circumstances and the nature of the inspection.
Boyd said that while there may be situations where a company could reasonably request additional time, especially for a significant and unexpected event affecting an essential inspection participant, manufacturers should still be prepared to proceed.
“If a person critical to the inspection had a legitimate emergency and they had to be out for a week or two, it would be reasonable to reach out to the FDA if it was a pre-announced inspection,” he said. “It would be fine to say, ‘Our lead for quality is out. Can we reschedule this inspection for the following week or the week after?’”
Nevertheless, Boyd stressed that manufacturers should not rely on the possibility of an FDA postponement and “should be prepared to move forward with an inspection.”
